{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:18:55Z","timestamp":1789730335609,"version":"4.0.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the effect of oncology services rendered by clinical pharmacists on reducing chemotherapy-induced nausea and vomiting (CINV) and improving overall treatment experiences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted using studies retrieved from PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Research Information Sharing Service (RISS). The incidence and severity of CINV were evaluated as primary outcomes. Secondary outcomes were patient adherence, patient satisfaction, quality of life (QoL), emergency department (ED) visits, hospitalizations, and costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 12 studies were selected for systematic review, with 8 studies eligible for meta-analysis. We found that clinical pharmacy services contributed to preventing and alleviating CINV as well as improving patient\u2019s medication adherence, treatment satisfaction, and QoL, reducing hospital visits, and achieving cost savings. In the meta-analysis, pharmacists\u2019 interventions were notably effective in reducing the incidence of nausea (odds ratio [OR], 1.917; 95% CI, 1.243-2.955; P = 0.003) and vomiting (OR, 2.491; 95% CI, 1.199-5.177; P = 0.014) during overall treatments periods relative to results in control groups. In addition, the impact of clinical pharmacy services on CINV control was greater during the delayed phase compared to the acute phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated the important role of clinical pharmacy services in controlling CINV and enhancing the overall treatment experience for patients with cancer. Further studies with standardized pharmacists\u2019 services and outcome measures are needed to validate our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae237","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T18:37:57Z","timestamp":1724783877000},"page":"e131-e147","source":"Crossref","is-referenced-by-count":6,"title":["Impact of oncology pharmacy services on the management of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"82","author":[{"given":"Yejin","family":"Shin","sequence":"first","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangyoon","family":"Shin","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejeong","family":"Ryu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyi","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunkyung Euni","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"4","key":"2026073004115735500_CIT0001","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/cncr.20423","article-title":"Cancer patients\u2019 expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices","volume":"101","author":"Hofman","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"2026073004115735500_CIT0002","doi-asserted-by":"publisher","first-page":"e1021","DOI":"10.1200\/OP.20.00947","article-title":"Impact of oral chemotherapy management program on capecitabine toxicity management","volume":"17","author":"Nhean","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"2026073004115735500_CIT0003","doi-asserted-by":"publisher","first-page":"385","DOI":"10.18553\/jmcp.2012.18.5.385","article-title":"Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy","volume":"18","author":"Chan","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"2026073004115735500_CIT0004","first-page":"296","article-title":"Impact of chemotherapy-associated nausea and vomiting on patients\u2019 functional status and on costs: survey of five Canadian centres","volume":"149","author":"O\u2019Brien","year":"1993","journal-title":"CMAJ"},{"issue":"12","key":"2026073004115735500_CIT0005","doi-asserted-by":"publisher","first-page":"e2288","DOI":"10.1002\/onco.13978","article-title":"Quality of life associated with nausea and vomiting from anthracycline-based chemotherapy: a pooled data analysis from three prospective trials","volume":"26","author":"Yeo","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"2026073004115735500_CIT0006","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cncr.22823","article-title":"Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy","volume":"110","author":"Tina Shih","year":"2007","journal-title":"Cancer"},{"key":"2026073004115735500_CIT0007","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"2026073004115735500_CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-907673-58-0_2","article-title":"Pathophysiology and classification of chemotherapy-induced nausea and vomiting","volume-title":"Prevention of Nausea and Vomiting in Cancer Patients","author":"Aapro","year":"2013"},{"key":"2026073004115735500_CIT0009","article-title":"Antiemesis (version: 1.2024)","volume-title":"NCCN Clinical Practice Guidelines in Oncology [proprietary data]","author":"National Comprehensive Cancer Network","year":"2024"},{"issue":"24","key":"2026073004115735500_CIT0010","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2026073004115735500_CIT0011","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"2026073004115735500_CIT0012","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"issue":"11","key":"2026073004115735500_CIT0013","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00520-019-04697-1","article-title":"Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey","volume":"27","author":"Dielenseger","year":"2019","journal-title":"Support Care Cancer"},{"issue":"9","key":"2026073004115735500_CIT0014","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support Care Cancer"},{"issue":"5","key":"2026073004115735500_CIT0015","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.sapharm.2023.01.006","article-title":"Practicing and evaluating clinical pharmacy in oncology: where are we now? A scoping review","volume":"19","author":"Sourisseau","year":"2023","journal-title":"Res Social Adm Pharm"},{"issue":"8","key":"2026073004115735500_CIT0016","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1177\/1078155219859424","article-title":"Demonstrating the value of the oncology pharmacist within the healthcare team","volume":"25","author":"Segal","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"2026073004115735500_CIT0017","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/bcp.13085","article-title":"Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis","volume":"82","author":"Renaudin","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2026073004115735500_CIT0018","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/1078155220976801","article-title":"Impact of clinical pharmacy in oncology and hematology centers: a systematic review","volume":"27","author":"Oliveira","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2026073004115735500_CIT0019","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.japh.2020.12.005","article-title":"Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: a systematic literature review","volume":"61","author":"Passey","year":"2021","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"7","key":"2026073004115735500_CIT0020","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jpain.2022.02.002","article-title":"Pharmacist involvement in cancer pain management: a systematic review and meta-analysis","volume":"23","author":"Shrestha","year":"2022","journal-title":"J Pain"},{"key":"2026073004115735500_CIT0021","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"2026073004115735500_CIT0022","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J Med Libr Assoc"},{"key":"2026073004115735500_CIT0023","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.3208","article-title":"Clinical pharmacy services in ambulatory oncology: an environmental scan of the Canadian practice landscape","author":"Tibensky","year":"2022","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"2026073004115735500_CIT0024","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/0145445516673998","article-title":"Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data","volume":"41","author":"Drevon","year":"2017","journal-title":"Behav Modif"},{"issue":"6","key":"2026073004115735500_CIT0025","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/0145445516645763","article-title":"Reliability, validity, and usability of data extraction programs for single-case research designs","volume":"40","author":"Moeyaert","year":"2016","journal-title":"Behav Modif"},{"key":"2026073004115735500_CIT0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/9780470743386.ch13","article-title":"Fixed-effect versus random-effects models","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"issue":"4","key":"2026073004115735500_CIT0027","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1213\/ANE.0000000000001596","article-title":"Publication bias: the elephant in the review","volume":"123","author":"Dalton","year":"2016","journal-title":"Anesth Analg"},{"key":"2026073004115735500_CIT0028","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026073004115735500_CIT0029","author":"National Institutes of Health"},{"key":"2026073004115735500_CIT0030","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"2026073004115735500_CIT0031","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s00520-012-1385-z","article-title":"Pharmaceutical care for patients with breast and ovarian cancer","volume":"20","author":"Liekweg","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"2026073004115735500_CIT0032","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-2753.2011.01665.x","article-title":"Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic","volume":"18","author":"Iihara","year":"2012","journal-title":"J Eval Clin Pract"},{"issue":"12","key":"2026073004115735500_CIT0033","first-page":"5549","article-title":"Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk","volume":"33","author":"Fujii","year":"2013","journal-title":"Anticancer Res"},{"issue":"2","key":"2026073004115735500_CIT0034","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11096-014-9915-z","article-title":"Influence of pharmaceutical care on the delayed emesis associated with chemotherapy","volume":"36","author":"Caracuel","year":"2014","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2026073004115735500_CIT0035","doi-asserted-by":"publisher","first-page":"999","DOI":"10.21873\/anticanres.13205","article-title":"Usefulness of implementing comprehensive pharmaceutical care for metastatic renal cell carcinoma outpatients treated with pazopanib","volume":"39","author":"Todo","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"2026073004115735500_CIT0036","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1078155220988333","article-title":"Impact of oncology pharmacist services on humanistic outcome in patients with breast cancer","volume":"28","author":"Khadela","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"2026073004115735500_CIT0037","doi-asserted-by":"publisher","first-page":"e115879","DOI":"10.1371\/journal.pone.0115879","article-title":"Pharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: a single arm intervention study","volume":"9","author":"Suzuki","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2026073004115735500_CIT0038","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0897190014557626","article-title":"Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management","volume":"29","author":"Hansen","year":"2016","journal-title":"J Pharm Pract"},{"issue":"4","key":"2026073004115735500_CIT0039","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/1078155218765629","article-title":"A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics","volume":"25","author":"Jackson","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"2026073004115735500_CIT0040","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/10781552211029702","article-title":"Implementation of a clinical pharmacist-led service to optimize management of refractory chemotherapy-induced nausea and vomiting in adult hematology\/oncology clinic","volume":"28","author":"Quinn","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"18","key":"2026073004115735500_CIT0041","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1200\/JCO.20.03088","article-title":"The randomized AMBORA trial: impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents","volume":"39","author":"D\u00fcrr","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026073004115735500_CIT0042","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","article-title":"Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study","volume":"23","author":"Escobar","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"2026073004115735500_CIT0043","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00520-014-2373-2","article-title":"Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries","volume":"23","author":"Hsieh","year":"2015","journal-title":"Support Care Cancer"},{"issue":"2","key":"2026073004115735500_CIT0044","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12482","article-title":"Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan","volume":"30","author":"Baba","year":"2017","journal-title":"Dis Esophagus"},{"issue":"1","key":"2026073004115735500_CIT0045","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer"},{"issue":"suppl 2","key":"2026073004115735500_CIT0046","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1136\/ejhpharm-2020-002600","article-title":"Clinical pharmacists\u2019 services, role and acceptance: a national Swedish survey","volume":"28","author":"Eriksson","year":"2021","journal-title":"Eur J Hosp Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae237\/59016783\/zxae237.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/3\/e131\/59016783\/zxae237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/3\/e131\/59016783\/zxae237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:12:05Z","timestamp":1785399125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/3\/e131\/7743287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,28]]},"published-print":{"date-parts":[[2025,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae237","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,1]]},"published":{"date-parts":[[2024,8,28]]}}}